Abstract
The cancer originated from large bowel represents a widespread cancer along the world and a considerable percentage of new cases are diagnosed with distant disease. Recently, the detection of “clever” medicaments such as focused therapy was the outcome of an improved comprehension of the procedures that transform physiological tissues to tumor. The family of focused medication includes medicaments that specifically affect specific molecular routes implicated in the production of the tumor and its development. The new natural substances aim at inhibiting the procedure of angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February 26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as primary therapy in patients with large bowel tumor and distant metastases is analysed.
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Current Cancer Therapy Reviews
Title:Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy
Volume: 11 Issue: 2
Author(s): Georgios Koukourakis, Georgios Zacharias and Aristides Petridis
Affiliation:
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Abstract: The cancer originated from large bowel represents a widespread cancer along the world and a considerable percentage of new cases are diagnosed with distant disease. Recently, the detection of “clever” medicaments such as focused therapy was the outcome of an improved comprehension of the procedures that transform physiological tissues to tumor. The family of focused medication includes medicaments that specifically affect specific molecular routes implicated in the production of the tumor and its development. The new natural substances aim at inhibiting the procedure of angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February 26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as primary therapy in patients with large bowel tumor and distant metastases is analysed.
Export Options
About this article
Cite this article as:
Koukourakis Georgios, Zacharias Georgios and Petridis Aristides, Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711666151022203012
DOI https://dx.doi.org/10.2174/1573394711666151022203012 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Functional Food with Some Health Benefits, So Called Superfood: A Review
Current Nutrition & Food Science Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology In Vitro and In Vivo Evaluation of Guar Gum-Based Matrix Tablets of Rofecoxib for Colonic Drug Delivery
Current Drug Delivery T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Mechanisms of Anorexia Cancer Cachexia Syndrome and Potential Benefits of Traditional Medicine and Natural Herbs
Current Pharmaceutical Biotechnology Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets QSAR Multi-Target in Drug Discovery: A Review
Current Computer-Aided Drug Design The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Feasibility of Assam Bora Rice Starch as a Compression Coat of 5-Fluorouracil Core Tablet for Colorectal Cancer
Current Drug Delivery Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Current Pharmaceutical Design Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from <i>Scorzanera Undulata</i> Tubers in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry